Access Conditions DEA Therapy 
The Cannigma
MAY 15, 2023
Ketamine has a long safety record as an anesthetic since the 1980s, and it has also been successfully used “off-label” for over a decade to treat conditions such as anxiety, depression, OCD, and PTSD, among others. 1 Related Stories What’s the deal with ketamine? 1 Related Stories What’s the deal with ketamine?
Veriheal
JUNE 29, 2021
In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine. The FDA refers to this program as the expanded access program on their website. A Push by Patients. Patients Are Not In This Alone.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
NOVEMBER 27, 2021
So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.” The post DMT Therapy: Coming to a Clinic Near You?
Cannabis Law Report
OCTOBER 4, 2021
Advanced Illness , Oregon Psilocybin Advisory Board , Oregon Psilocybin Services Act , Psilocybin , Psilocybin Therapy , Psychedelics , Right To Try. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions.
Veriheal
FEBRUARY 23, 2024
As the Drug Enforcement Administration (DEA) and federal government draw closer to moving cannabis from a Schedule I to a Schedule III substance , more groups have begun to put their weight behind the movement. Countless veterans suffer from these ailments, and, as such, are pushing for access to as many treatments and therapies as possible.
MJ Business Attorneys
JUNE 29, 2018
The FDA approved Epidiolex as a prescription drug to be used to treat two severe epileptic conditions, Lennox-Gastaut syndrome and Dravet syndrome. Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. In the recent case Hemp Industries Associations v.
Canna Law Blog
NOVEMBER 6, 2021
But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. For two decades, U.S.
Expert insights. Personalized for you.
78 
Let's personalize your content